AHA blog: PhRMA report misleads on drug costs
Instead of attacking hospitals and health systems caring for patients during the COVID-19 pandemic, PhRMA should instead focus on lowering the costs of drugs for Americans, writes AHA Executive Vice President Tom Nickels.
Related News Articles
Headline
Deceptively branded as an effort to save the 340B program, a legislative campaign by the Pharmaceutical Research and Manufacturers of America, National…
Headline
The Centers for Medicare & Medicaid Services this week released for comment initial guidance implementing a program for Medicare to negotiate prices…
Headline
This April through June under the Inflation Reduction Act, Medicare will reduce the coinsurance amount for 27 Part B prescription drugs from 20% to somewhere…
Headline
Medicare should continue to pay average sales price plus 6% for most separately payable Part B drugs, but cap ASP inflation, AHA told the Medicare Payment…
Headline
The CMS Innovation Center will test three new models to see whether they lower high drug costs, the Centers for Medicare & Medicaid Services announced…
Headline
Following the recent district court decision to remand to the Department of Health and Human Services the question of how to repay 340B hospitals for…